Inside a research in breast cancer cells, the combination of lapatinib, a dual HER2/neu and EGFR tyrosine kinase inhibitor, with INK128 prevented the two HER2 and HER3 phosphorylation induced by INK128 and made synergistic induction of mobile Demise in various HER2-favourable cell lines immune to trastuzumab and lapatinib. In vivo https://jamesx752imq4.snack-blog.com/profile